Stocks Health care MTNB
NYSE · Health careMatinas BioPharma Holdings, Inc. (MTNB)
It posted a net loss of $6.7M. At June 30, 2026 it held $761K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Matinas BioPharma Holdings, Inc.
- Net worth
- Matinas BioPharma Holdings, Inc. has a market value (market cap) of $16M at the latest share price, and shareholders' equity of $1.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2023 revenue was $1.1M (-65.6% year on year), with a net loss of $22.9M.
- Cash flow
- In fiscal 2025 operations used $7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Matinas BioPharma Holdings, Inc.'s next report was expected around November 9, 2026 and is not on file with the SEC yet.
What Matinas BioPharma Holdings, Inc. does
Matinas BioPharma Holdings, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker MTNB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$10.3M | -$2.00 | n/a |
| 2024 | n/a | -$24.3M | -$4.98 | n/a |
| 2023 | $1.1M | -$22.9M | -$5.28 | -$15.5M |
| 2022 | $3.2M | -$21M | -$4.80 | -$20M |
| 2021 | $33K | -$23.3M | -$5.28 | -$15.5M |
| 2020 | $158.3K | -$22.4M | -$5.76 | -$17.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Matinas BioPharma Holdings, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 28, 2026
- September 16, 2026Other event 8-K
- September 4, 2026
- August 25, 2026Form 425 filing 425
- August 13, 2026
- August 13, 2026Activist stake changed SCHEDULE 13D/A
- August 4, 2026Form 425 filing 425
- July 30, 2026Form 425 filing 425
- July 29, 2026Form 425 filing 425
- July 24, 2026
Insider trades
What the people running Matinas BioPharma Holdings, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 10, 2026 | Stern Adam K10% owner | Exercised optionsindirect | 344,710 | $120.6K |
| July 10, 2026 | Stern Adam K10% owner | Exercised optionsindirect | 630,335 | $220.6K |
Who owns MTNB
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Robert J. Eide13D, may seek influence with 1 related filers | 9.99% | April 10, 2025 |
| Stern Adam K13D, may seek influence with 1 related filers | 9.99% | August 13, 2026 |
| Lazar David E.13G, passive | 9.81% | August 19, 2025 |
| Hezbay Holdings LLC13G, passive | 9.54% | July 14, 2026 |
Largest institutional holders
Insiders
1 insiders reported holding 743,785 shares in total, about $810K at the last price.
| Holder | Shares |
|---|---|
| Stern Adam K10% owner | 743,785743,785 held indirectly |
Questions about MTNB
What does Matinas BioPharma Holdings, Inc. do?
Matinas BioPharma Holdings, Inc. is a company in the Health care sector, listed on NYSE as MTNB. Its shares trade on NYSE under the ticker MTNB.
What is Matinas BioPharma Holdings, Inc.'s net worth?
Matinas BioPharma Holdings, Inc. has a market value (market cap) of $16M at the latest share price, and shareholders' equity of $1.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Matinas BioPharma Holdings, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $6.7M.
When did Matinas BioPharma Holdings, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the shareholder rights changed from September 28, 2026.
When is Matinas BioPharma Holdings, Inc.'s next earnings report?
Matinas BioPharma Holdings, Inc.'s next report was expected around November 9, 2026 and is not on file with the SEC yet.
Similar companies
Compare MTNB with
Follow MTNB
Get an email when Matinas BioPharma Holdings, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Matinas BioPharma Holdings, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.